Market Research Logo

Global Chemotherapy-Induced Nausea and Vomiting (CINV) & Postoperative Nausea and Vomiting (PONV) Market: Industry Analysis & Outlook (2018-2022)

Global Chemotherapy-Induced Nausea and Vomiting (CINV) & Postoperative Nausea and Vomiting (PONV) Market: Industry Analysis & Outlook (2018-2022)

Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides chemotherapy, there are various types of factors that puts a patient high risk for CINV including female sex, history of alcohol use, CINV & motion sickness and anxiety or depression.

Postoperative Nausea and Vomiting (PONV) is referred to as a situation in which an inpatient experiences nausea and/or vomiting within the first 24-48 hours after undergoing surgery with general anesthesia. The incidence of PONV is 30% in the all post-surgical patients and 80% in high-risk patients. PONV is caused due to various factors including anesthetic choices, patient and surgery-specific. Treatment of PONV is done through prophylaxis and rescue treatment.

The U.S. emerged as a major region for the CINV & PONV market due to rising healthcare concerns and expenditure of the U.S. populace and growing CINV & PONV patient population.

The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.

The report “Global Chemotherapy-Induced Nausea and Vomiting (CINV) & Postoperative Nausea and Vomiting (PONV) Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the U.S., Europe along with the global market. The report profiles the key players of the market including Merck & Co., Inc., Kirin Holding Company Limited (ProStrakan), Eisai Co., Ltd. and Helsinn Holding S.A.


1. CINV & PONV Overview
1.1 CINV
Table 1: Sub-Categories of CINV
1.2 PONV
Table 2: Causes of PONV
2. Global CINV & PONV Market
2.1 Global CINV Market Forecast by Value
Table 3: Global CINV Market Forecast by Value (2017-2022)
2.2 Global PONV Market Forecast by Value
Table 4: Global PONV Market Forecast by Value (2017-2022)
3. Regional CINV & PONV Market
3.1 The U.S. CINV & PONV Market Forecast by Value
Table 5: The U.S. CINV & PONV Market Forecast by Value (2017-2022)
3.2 The U.S. CINV & PONV Drugs Revenue by Categories
Table 6: The U.S. CINV & PONV Drugs Revenue by Categories (2017)
3.3 The U.S. CINV & PONV Drugs Revenue
3.3.1 The U.S. Aloxi Drug Revenue
Table 7: The U.S. Aloxi Drug Revenue (2013-2017)
3.3.2 The U.S. Aloxi Drug Revenue Forecast
Table 8: The U.S. Aloxi Drug Revenue Forecast (2018-2022)
3.3.3 The U.S. Emend Drug Revenue Forecast
Table 9: The U.S. Emend Drug Revenue Forecast (2017-2022)
3.4 The U.S. CINV Drugs Revenue
3.4.1 The U.S. Sustol Drug Revenue Forecast
Table 10: The U.S. Sustol Drug Revenue Forecast (2017-2022)
3.4.2 The U.S. Cinvanti Drug Revenue Forecast
Table 11: The U.S. Cinvanti Drug Revenue Forecast (2018-2022)
3.4.3 The U.S. Varubi Oral Drug Revenue Forecast
Table 12: The U.S. Varubi Oral Drug Revenue Forecast (2018-2022)
3.4.4 The U.S. Varubi IV Drug Revenue Forecast
Table 13: The U.S. Varubi IV Drug Revenue Forecast (2018-2022)
3.5 The U.S. PONV Patient Population Forecast
Table 14: The U.S. PONV Patient Population Forecast (2018-2022)
3.6 The U.S. PONV Drugs Revenue
3.6.1 The U.S. Baremsis Drug Revenue Forecast
Table 15: The U.S. Baremsis Drug Revenue Forecast (2019-2023)
3.7 Europe CINV Drugs Revenue
3.7.1 Europe Varuby Oral Drug Revenue Forecast
Table 16: Europe Varuby Oral Drug Revenue Forecast (2018-2022)
3.7.2 Europe Varuby IV Drug Revenue Forecast
Table 17: Europe Varuby IV Drug Revenue Forecast (2018-2022)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Cancer Incidence
Table 18: Global Cancer New Cases (2013-2017)
4.1.2 Growing Female Population
Table 19: Global Female Population* (2013-2017)
4.1.3 Increasing Pharmaceutical R&D Spending
Table 20: Global Pharmaceutical R&D Spending (2013-2017)
4.1.4 Growing Healthcare Expenditure
Table 21: Global Healthcare Expenditure (2013-2017)
4.1.5 Accelerating Economic Growth
Table 22: Global GDP Per Capita (2013-2017)
4.2 Key Trends and Developments
4.2.1 Progressing Drugs under Pipeline
Table 23: Drugs under Development for CINV & PONV
4.2.2 High Demand for Combination Therapy
4.2.3 Increasing Preference for Pressure Point Therapy
4.3 Challenges
4.3.1 Entry of Generics
Table 24: Generics for CINV Therapies (2016-2018)
4.3.2 Stringent Regulations
4.3.3 Treatment Cost
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
Table 25: Key Players – Revenues Comparison (2017)
5.1.2 CINV & PONV Treatment Cost Comparison by Company
Table 26: CINV & PONV Treatment Cost Comparison by Company (2018)
5.2 The U.S.
5.2.1 The U.S. CINV and PONV Market Share by Company
Table 27: The U.S. CINV and PONV Market Share by Company (2017)
6. Company Profiles
6.1 Merck & Co., Inc.
6.1.1 Business Overview
Table 28: Merck & Co., Inc. Net Sales by Business Segments (2017)
6.1.2 Financial Overview
Table 29: Merck & Co., Inc. Net Sales and Net Income (2013-2017)
6.1.3 Business Strategies
Table 30: Merck & Co., Inc. Research and Development Expenditures (2015-2017)
6.2 Eisai Co., Ltd.
6.2.1 Business Overview
Table 31: Eisai Co., Ltd. Revenues by Business Segments (2017*)
6.2.2 Financial Overview
Table 32: Eisai Co., Ltd. Revenues and Net Profit (2013-2017*)
6.2.3 Business Strategies
Table 33: Eisai Co., Ltd Research and Development Expenditures (2015-2017)
6.3 Kirin Holding Company, Limited (ProStrakan)
6.3.1 Business Overview
Table 34: Kirin Holding (ProStrakan) Net Sales by Business Segments (2017)
6.3.2 Financial Overview
Table 35: Kirin Holding (ProStrakan) Net Sales and Net Income (Loss) (2013-2017)
6.3.3 Business Strategies
Table 36: Kirin Holding Company, Limited (ProStrakan) A&P Expenditures (2015-2017)
6.4 Helsinn Holding S.A.
6.4.1 Business Overview
Table 37: Helsinn Holding S.A. Drug Pipeline (2018)
6.4.2 Financial Overview
Table 38: Helsinn Holding S.A. Net Sales (2013-2016)
6.4.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report